Via its patented Fynomer®-technoloy, Covagen, founded in 2007 as a spin-off company of ETH Zurich (Swiss), develops bispecific FynomAbs, proteins that have the ability to fuse to multiple sites on an antibody. This technology results in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. In August 2014, Covagen was acquired by Cilag GmbH International.
- Aktivität: Development of bispecific FynomAbs
- Website: www.covagen.com
- Location: Switzerland
- Investititionsjahr: 2013
- Plattform: Health & Care